menu
    • menu
    [{"orgOrder":0,"company":"GSK","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Defence Materials Technology Centre","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Defence Materials Technology Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Defence Materials Technology Centre \/ Certara","highestDevelopmentStatusID":"11","companyTruncated":"Defence Materials Technology Centre \/ Certara"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Washington University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"HaEmek Medical Center, Israel","sponsor":"T MAY BIOPHARMA LTD.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HaEmek Medical Center, Israel","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"HaEmek Medical Center, Israel \/ T MAY BIOPHARMA LTD.","highestDevelopmentStatusID":"9","companyTruncated":"HaEmek Medical Center, Israel \/ T MAY BIOPHARMA LTD."},{"orgOrder":0,"company":"Uni-Pharma SA","sponsor":"Athens General Hospital Hippokrateio | Sotiria Thoracic Diseases Hospital | Sismanoglio General Hospital | Divine Providence Hospital Pammakaristos | AHEPA University Hospital | University Hospital of Ioannina | Corfu General Hospital Agia Irini","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GREECE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Uni-Pharma SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Uni-Pharma SA \/ Athens General Hospital Hippokrateio | Sotiria Thoracic Diseases Hospital | Sismanoglio General Hospital | Divine Providence Hospital Pammakaristos | AHEPA University Hospital | University Hospital of Ioannina | Corfu General Hospital Agia Irini","highestDevelopmentStatusID":"8","companyTruncated":"Uni-Pharma SA \/ Athens General Hospital Hippokrateio | Sotiria Thoracic Diseases Hospital | Sismanoglio General Hospital | Divine Providence Hospital Pammakaristos | AHEPA University Hospital | University Hospital of Ioannina | Corfu General Hospital Agia Irini"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"Institut Pasteur | Institut Pasteur de Madagascar | Armauer Hansen Research Institute (AHRI), Ethiopia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ Institut Pasteur | Institut Pasteur de Madagascar | Armauer Hansen Research Institute (AHRI), Ethiopia","highestDevelopmentStatusID":"10","companyTruncated":"London School of Hygiene & Tropical Medicine \/ Institut Pasteur | Institut Pasteur de Madagascar | Armauer Hansen Research Institute (AHRI), Ethiopia"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Population Health Research Institute \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ US Government","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ US Government"}]

    Find Clinical Drug Pipeline Developments & Deals for Delagil

    Menu

    Delagil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            London School of Hygiene & Tropical Medicine

                            Country arrow
                            Process Development
                            Not Confirmed

                            London School of Hygiene & Tropical Medicine

                            Country arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Institut Pasteur | Institut Pasteur de Madagascar | Armauer Hansen Research Institute (AHRI), Ethiopia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 11, 2025

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Institut Pasteur | Institut Pasteur de Madagascar | Armauer Hansen Research Institute (AHRI), Ethiopia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GSK

                            United Kingdom arrow
                            Process Development
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine Succinate,Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GSK and MMV Launch New Medicine to Prevent Plasmodium vivax Malaria Relapse

                            Details : Kozenis (tafenoquine) is the first single-dose, oral, hematin polymerization inhibitor co-administered with chloroquine for preventing P. vivax malaria relapse, launched in Thailand and Brazil.

                            Product Name : Kozenis

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 07, 2024

                            Lead Product(s) : Tafenoquine Succinate,Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Defence Materials Technology Centre

                            Australia arrow
                            Process Development
                            Not Confirmed

                            Defence Materials Technology Centre

                            Australia arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Certara

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Worke...

                            Details : Certara will support the DMTC led clinical trial by analyzing study data to develop mathematical models to understand viral time course and factors impacting drug exposure and prophylactic response.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 05, 2020

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Certara

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Washington University School of Medicine

                            U.S.A arrow
                            Process Development
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rising Pharmaceuticals to Support Global Clinical Trial Conducted by the CROWN Collaborative

                            Details : An international study named “CROWN CORONATION” aims to include up to 55,000 subjects and is designed to assess the effectiveness of multiple dose ranges of chloroquine to prevent SARS-CoV-2 infection in frontline healthcare workers.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 18, 2020

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Population Health Research Institute

                            Country arrow
                            Process Development
                            Not Confirmed

                            Population Health Research Institute

                            Country arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate,Azithromycin,Interferon Beta 1B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Bayer AG

                            Deal Size : $1.1 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-1...

                            Details : Bayer and PHRI together will conduct two studies that will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 21, 2020

                            Lead Product(s) : Chloroquine Phosphate,Azithromycin,Interferon Beta 1B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Bayer AG

                            Deal Size : $1.1 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Uni-Pharma SA

                            Greece arrow
                            Process Development
                            Not Confirmed

                            Uni-Pharma SA

                            Greece arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Athens General Hospital Hippokrateio | Sotiria Thoracic Diseases Hospital | Sismanoglio General Hospital | Divine Providence Hospital Pammakaristos | AHEPA University Hospital | University Hospital of Ioannina | Corfu General Hospital Agia Irini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, N...

                            Details : Undisclosed

                            Product Name : Unikinon

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 14, 2020

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Athens General Hospital Hippokrateio | Sotiria Thoracic Diseases Hospital | Sismanoglio General Hospital | Divine Providence Hospital Pammakaristos | AHEPA University Hospital | University Hospital of Ioannina | Corfu General Hospital Agia Irini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HaEmek Medical Center, Israel

                            Country arrow
                            Process Development
                            Not Confirmed

                            HaEmek Medical Center, Israel

                            Country arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : T MAY BIOPHARMA LTD.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chloroquine for Mild Symptomatic and Asymptomatic COVID-19

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 03, 2020

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : T MAY BIOPHARMA LTD.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bayer AG

                            Germany arrow
                            Process Development
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : US Government

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bayer Partners with U.S. Government on Major Product Donation to Fight Coronavirus

                            Details : Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug’s use in the U.S.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 19, 2020

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : US Government

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lilia Gonzalez Ceron

                            Country arrow
                            Process Development
                            Not Confirmed

                            Lilia Gonzalez Ceron

                            Country arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Instituto de Diagnóstico y Referencia Epidemiológicos, Mexico | Centro Nacional de Vigilancia Epidemiológica y control de enfermedades, Mexico | Jurisdicción Sanitaria VII, Chiapas, México | Pan American Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Malaria Treatment in Mexico

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 20, 2015

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Instituto de Diagnóstico y Referencia Epidemiológicos, Mexico | Centro Nacional de Vigilancia Epidemiológica y control de enfermedades, Mexico | Jurisdicción Sanitaria VII, Chiapas, México | Pan American Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bandim Health Project

                            Country arrow
                            Process Development
                            Not Confirmed

                            Bandim Health Project

                            Country arrow
                            Process Development
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic Study of Multi-dose Chloroquine

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 20, 2013

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth